

Learn about common and serious Tivicay side effects, including insomnia, headache, weight gain, and when you should contact your doctor right away.
Tivicay (Dolutegravir) is one of the most widely prescribed HIV medications in the world. It's effective, well-tolerated, and taken just once a day for most patients. But like any medication, it can cause side effects.
This guide covers the common side effects you might experience, the serious ones to watch for, and exactly when you should call your doctor. Knowing what to expect can help you stay calm and stay on treatment.
Most people who take Tivicay tolerate it well. In clinical trials, the most frequently reported side effects were mild and often improved over the first few weeks. Here's what you might notice:
Trouble sleeping is one of the most commonly reported side effects. It usually appears in the first few weeks of treatment. Tips that may help:
Mild headaches are common early in treatment. Over-the-counter pain relievers like acetaminophen are generally safe to use. If headaches are severe or don't go away, let your doctor know.
Some people feel more tired than usual when starting Tivicay. This typically improves as your body adjusts. Make sure you're getting enough sleep, staying hydrated, and eating well.
Mild nausea can occur, especially in the first few weeks. Taking Tivicay with food may help reduce stomach discomfort. If nausea is severe or causes vomiting, contact your provider.
Loose stools or diarrhea may happen but usually resolve on their own. Stay hydrated and talk to your doctor if it's persistent or severe.
Some patients report feeling lightheaded. Avoid driving or operating heavy machinery if you feel dizzy, and report it to your doctor if it continues.
While serious side effects are uncommon, they can happen. Know the warning signs so you can act quickly.
Stop taking Tivicay and seek medical attention right away if you experience:
Hypersensitivity reactions to Tivicay can affect multiple organs, including the liver and kidneys. If you've ever had an allergic reaction to Dolutegravir, you should not take Tivicay again.
Tivicay can cause liver inflammation in rare cases. Watch for these symptoms:
People with hepatitis B or C or other liver conditions may be at higher risk. Your doctor will monitor your liver function with regular blood tests.
Studies have shown that integrase inhibitors, including Dolutegravir, are associated with more weight gain compared to some other HIV drug classes. The weight gain can range from a few pounds to more significant changes over months or years.
If you notice unexpected weight gain, talk to your doctor. They can help determine if it's related to Tivicay and discuss strategies for management. Do not stop taking your medication without medical advice — an uncontrolled viral load is far more dangerous than moderate weight gain.
When you start HIV treatment and your immune system begins to recover, it may respond to infections that were previously hidden. This is called immune reconstitution inflammatory syndrome (IRIS). Symptoms depend on the underlying infection but can include fever, swollen lymph nodes, or worsening of previous symptoms.
This is actually a sign that your treatment is working, but it may need to be managed by your doctor. Report any new or worsening symptoms after starting Tivicay.
In rare cases, Tivicay can cause elevated levels of creatine kinase (a muscle enzyme). Severe cases can lead to rhabdomyolysis — a serious condition where muscle tissue breaks down. Seek medical attention if you have:
The FDA issued a safety communication about a potential risk of neural tube defects with Dolutegravir use around the time of conception. Later studies (including 2023 data) were more reassuring and showed no significantly increased risk in the U.S. population. However, the label still advises discussing risks and benefits with patients of childbearing potential.
If you're pregnant or planning to become pregnant, talk to your doctor about whether Tivicay is right for you. Never stop HIV medication without medical guidance.
Tivicay is approved for children weighing at least 3 kg (about 6.6 lbs). Tivicay PD dispersible tablets (5 mg) are available for pediatric patients. Side effects in children are generally similar to those in adults.
Compared to older HIV drug classes like protease inhibitors or NNRTIs, Tivicay and other integrase inhibitors tend to cause fewer side effects overall. That's one reason INSTIs have become the preferred first-line treatment in most HIV guidelines.
However, if you're experiencing side effects that affect your quality of life, there are alternatives to Tivicay your doctor can consider, including Biktarvy, Dovato, or the long-acting injectable Cabenuva.
Call your doctor's office if you have:
Go to the emergency room if you have:
Tivicay works by blocking HIV integrase — the enzyme the virus needs to insert its DNA into your cells. Because this mechanism is specific to the virus, Tivicay tends to cause fewer systemic side effects than drugs that work through broader mechanisms. Learn more about how Tivicay works in our detailed explainer.
Most people who take Tivicay experience mild side effects that improve within the first few weeks. Serious side effects are rare but important to recognize. The benefits of staying on HIV treatment — including an undetectable viral load and a near-normal life expectancy — far outweigh the risks for most patients.
If you're having trouble with side effects or need help finding Tivicay at an affordable price, visit MedFinder to check pharmacy availability and explore savings options.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.